Social Anxiety Disorder Clinical Trial
Official title:
Investigating Attentional Processes: Teleconferencing and Social Anxiety
Verified date | January 2024 |
Source | University of Texas at Austin |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study involves completing some online assessments and an intervention for social anxiety that all involve interactions with other people on a teleconferencing call.
Status | Completed |
Enrollment | 53 |
Est. completion date | June 30, 2022 |
Est. primary completion date | June 30, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: - Age 18-75 - Fluent in English because the data collection materials have not yet been standardized in other languages - Having access to a computer with a webcam and ability to record audio - Personal Report of Communication Apprehension > 80 - Leibowitz Social Anxiety Scale > 30 - Meets DSM-5 Criteria for Social Anxiety Disorder Exclusion Criteria: - Significant visual impairment precluding the use of the eye tracking equipment - Current, or history of bipolar disorder; current, or history of psychosis |
Country | Name | City | State |
---|---|---|---|
United States | Laboratory for the Study of Anxiety Disorders, University of Texas at Austin | Austin | Texas |
Lead Sponsor | Collaborator |
---|---|
University of Texas at Austin |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Personal Report of Communication Apprehension Questionnaire | Assessment of communication concerns, range of scores is 24-120; higher scores are worse | prior to the first treatment session, an average of 2 days | |
Primary | Personal Report of Communication Apprehension Questionnaire | Assessment of communication concerns, range of scores is 24-120; higher scores are worse | 1-week follow-up | |
Primary | Personal Report of Communication Apprehension Questionnaire | Assessment of communication concerns, range of scores is 24-120; higher scores are worse | 2-week follow-up | |
Primary | Leibowitz Social Anxiety Scale Questionnaire | Assessment of general social anxiety, range of scores is 0-144; higher scores are worse | prior to the first treatment session, an average of 2 days | |
Primary | Leibowitz Social Anxiety Scale Questionnaire | Assessment of general social anxiety, range of scores is 0-144; higher scores are worse | 1-week follow-up | |
Primary | Leibowitz Social Anxiety Scale Questionnaire | Assessment of general social anxiety, range of scores is 0-144; higher scores are worse | 2-week follow-up |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06274112 -
Using TMS to Understand Neural Processes of Social Motivation
|
N/A | |
Completed |
NCT02554929 -
Treatment of Social Anxiety Disorder and Selective Mutism
|
N/A | |
Completed |
NCT00684541 -
Interpretation Modification Program for Social Phobia
|
N/A | |
Completed |
NCT00684320 -
Attention Disengagement Training for Social Phobia
|
N/A | |
Completed |
NCT03247075 -
Internet-delivered CBT vs Internet-delivered Support and Counseling for Youth With Social Anxiety Disorder - An RCT
|
N/A | |
Completed |
NCT02811458 -
Clinical Trial of Transdiagnostic Cognitive-Behavior Therapy for Anxiety Disorders
|
N/A | |
Withdrawn |
NCT04622930 -
Waitlist-Control Trial of Smartphone CBT for Social Anxiety Disorder (SAD)
|
N/A | |
Active, not recruiting |
NCT05018312 -
Modified Collaborative Assessment VS Standard Assessment on Readiness For Psychotherapy Among Patients With Anxiety
|
N/A | |
Active, not recruiting |
NCT05124639 -
Clinical Trial of a Group Self-management Support Program for Anxiety Disorders
|
N/A | |
Completed |
NCT05858294 -
The Safety, Acceptability and Efficacy of Alena
|
N/A | |
Active, not recruiting |
NCT05600114 -
Cannabidiol (CBD) for the Treatment of Social Anxiety Disorder
|
Phase 2 | |
Not yet recruiting |
NCT06081348 -
Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders
|
Phase 2 | |
Not yet recruiting |
NCT02924610 -
Brief Intervention to Reduce Fear
|
Phase 4 | |
Active, not recruiting |
NCT02592564 -
Brain Plasticity and Cellular Aging After Internet-delivered CBT for Social Anxiety Disorder
|
N/A | |
Recruiting |
NCT02305537 -
Building an Outcomes Assessment Infrastructure to Assess Anxiety Treatment
|
N/A | |
Terminated |
NCT03764644 -
Web-based Attention Bias Modification Treatment for Childhood Anxiety Disorders
|
N/A | |
Unknown status |
NCT01712321 -
Study of Vilazodone to Treat Social Anxiety Disorder
|
N/A | |
Completed |
NCT01320800 -
CBT for Social Anxiety Disorder Delivered by School Counselors
|
Phase 2 | |
Completed |
NCT00485615 -
An Open Label Trial of Omega 3(o3mega+Joy)in the Treatment of Social Phobia
|
Phase 2 | |
Completed |
NCT00773162 -
Flushing in Social Anxiety Disorder on Seroquel
|
Phase 3 |